• The Korean Journal of Nuclear Medicine
• /
• v.29 no.3
• /
• pp.319-327
• /
• 1995

$^{131}I$-metaiodobenzylguanidine(MIBG) has been used for the diagnosis and treatment of neural crest tumors. We report our experience with this agent in 8 patients[1 multiple endocrine neoplasia(MEN) type IIb; 2 malignant pheochromocytoma; 5 medullary thyroid carcinoma(MTC)]. The therapeutic procedure consisted of 30-200 mCi of $^{131}I-MIBG$ administered by slow I.V. infusion, given at 3-6 months intervals. Commutative activity ranged from 150 mCi to 410 mCi, in 1 to 4 courses. $^{131}I-MIBG$ therapy resulted in significant disease free interval in 1 malignant pheochromocytoma(no measurable lesion) after surgery; complete hormonal and tumoral response in 2 MTC(1 MEN IIb): stable disease in 1 recurred pheochromocytoma(MEN IIb): stable disease but symptomatic improvement in 1 MTC, progressive disease in 1 malignant pheochromocytoma and 2 MTC. The patients who showed progression appeared to have large inoperable tumors or postoperative remnant tumors.

• Journal of International Academy of Physical Therapy Research
• /
• v.11 no.1
• /
• pp.1999-2004
• /
• 2020

Background: Although studies on physical motor learning through motor imagery training have been conducted in various fields, studies on its effectiveness are still considered insufficient. Objective: To investigate the effect of motor imagery training and balance training on static balance of asymptomatic adults in their 20s. Design: A quasi-experimental study. Methods: Thirty-six adults in their 20s who passed the tandem stance test were randomized to the motor imagery training group (MIG, n=12), motor imagery with balance training group (MIBG, n=12), and balance training group (BG, n=12). Each group underwent their respective interventions three times a week for four weeks, and changes in static balance were analyzed using multivariate analysis of variance. Results: Trace length was significantly lower in the MIBG than in the MIG and BG (P<.05), and a significant reduction in trace length in the MIBG was observed after the intervention as compared to the baseline (P<.05). Furthermore, a significantly lower velocity was observed in the MIBG than in the MIG and BG (P<.05), and a significant reduction of velocity in the MIBG was more observed after the intervention compared to the baseline (P<.05). Conclusion: These results suggest that motor imagery training enhance static balance in healthy college students.

• The Korean Journal of Nuclear Medicine
• /
• v.26 no.2
• /
• pp.365-370
• /
• 1992

Pheochromocytomas are catecholamine producing tumors of neuroectoderrnal origin. Diagnosis of pheochromocytoma is significant due to potentially curable hypertension. But they have a significant associated morbidity due to uncontrolled hypertension and mortality since 10% are malignant. From Aug. 1989 to Jul. 1992, 12 patients of our institution had $^{131}I-MIBG$ scan during work up of suspected primary or recurrent pheochromocytoma. In our studies conclude that $^{131}I-MIBG$ scan is recommended as the initial localizing study of choice (especially for the detection of extraadrenal disease and postoperative recurrence) as a guide for CT and/or MR and specific functional confirmation of their findings.

• The Korean Journal of Nuclear Medicine
• /
• v.27 no.2
• /
• pp.161-164
• /
• 1993

• The Korean Journal of Nuclear Medicine
• /
• v.28 no.3
• /
• pp.402-406
• /
• 1994

Pheochromocytomas are catecholamine-producing tumors of neuroectodermal origin, and may arise wherever chromaffin cells are located. They are rare but potentially lethal and amenable to surgical cure. Once a clinical diagnosis has been established, localization becomes of importance to direct surgical approach. MIBG scintigraphy is the initial localizing procedure of choice, due to its ability to screen the entire body, especially in the detection of extraadrenal and recurrent pheochromocytoma. A case of recurrent extraadrenal pheochromocytoma diagnosed by $^{131}I$-MIBG scintigraphy is presented with review of the literature.

• The Korean Journal of Nuclear Medicine
• /
• v.26 no.1
• /
• pp.151-154
• /
• 1992

갈색종은 비교적 드문 종양으로 다발성으로 생기는 경우는 더욱 드물다. 갈색종은 수술로 90%이상 완치 가능한 질환이므로 수술전 종양의 위치와 범위를 정확히 확인하는 것 이 매우 중요하다. 저자들은 최근 파동하는 고혈압을 주소로 내원한 33세 남자환자에서 복부전산화 단층촬영술상 우측부신의 종양만을 확인할 수 있었으나, $^{131}I-MIBG$ 신티그라피에서는 우측 부신의 병소외에 골반강 내에 또다른 병소가 발견되어 골반강 전산화 단층촬영술을 추가로 시행하였고 이어 수술로써 확진된 이중병소의 갈색종 1예를 보고하는 바이다.

• The Korean Journal of Nuclear Medicine
• /
• v.24 no.2
• /
• pp.332-336
• /
• 1990

Pheochromocytoma occurs at all ages but is most common in young to midadult life. In adults 10 percent of pheochronocytoma are bilateral. And bilateral lesions are common in the familial syndromes; within Multiple Endocrine Neoplasia (MEN) kindreds over half with pheochromocytomas have bilateral lesions. We report a case of bilateral pheochromocytoma firstly detected by ultrasonogram. This 24-year-old male was normotensive and had symptoms of dilated cardiomyopathy and elevated VMA level. CT and MRI were performed to evaluate the tissue nature and associated abnormalities. $^{131}I-MIBG$ scan seems to be the imaging of choice in patients with suspected multicentric/bilateral or recurrent or metastatic pheochromocytomas.

• Nuclear Medicine and Molecular Imaging
• /
• v.40 no.2
• /
• pp.90-95
• /
• 2006

Neuroendocrine tumors (NETs) consist of a heterogeneous group of tumors that are able to uptake neuroamine and/or specific receptors, such as somatostatin receptors, which can play important roles of the localization and treatment of these tumors. When considering therapy with radionuclides, the best radioligand should be carefully investigated. $^{131}I$-MIBG and beta-particle emitter labeled somatostatin analogs are well established radionuclide therapy modalities for NETs. $^{111}In,\;^{90}Y\;and\;^{177}Lu$ radiolabeled somatostatin analogues have been used for treatment of NETs. Further, radionuclide therapy modalities, for example, radioimmunotherapy, radiolabeled peptides such as minigastrin are currently under development and in different phases of clinical investigation. for all radionuclides used for therapy, long-term and survival statistics are not yet available and only partial tumour responses have been obtained using $^{131}I$-MIBG and $^{111}In$-octreotide. Experimental results using $^{90}Y$-DOTA-lanreotide as well as $^{90}Y-DOTA-D-Phe1-Tyr^3-octreotide$ and/or $^{177}Lu-DOTA-Tyr^3-octreotate$ have indicated the possible clinical potential of radionuclides receptor-targeted radiotherapy it may be hoped that the efficacy of radionuclide therapy will be improved by co-administration of chemotherapeutic drugs whose antitumoral properties may be synergistic with that of irradiation.

• 대한핵의학회:학술대회논문집
• /
• 1990.04a
• /
• pp.190.1-190.1
• /
• 1990

• 대한핵의학회:학술대회논문집
• /
• 1995.05a
• /
• pp.210-210
• /
• 1995